

Novel Immunotherapeutic Effects of Topically Administered Ripasudil (K-115) on

Corneal Allograft Survival

Takenori Inomata, MD, PhD^{1,2,3,4,5*}, Keiichi Fujimoto, MD^{1,2,5}, Yuichi Okumura,

MD^{1,2,3,5}, Jun Zhu, MD¹, Kenta Fujio, MD^{1,2,5}, Hurrarnhon Shokirova, MD¹, Maria

Miura, MD^{1,5}, Mikiko Okano, MD¹, Toshinari Funaki, MD, PhD^{1,6}, Jaemyoung Sung,

MS^{1,7}, Naoko Negishi, PhD^{8,9}, and Akira Murakami, MD, PhD^{1,2,5}

Table S1. Primer sets for real-time PCR.

Gene	Forward (5' - 3')	Reverse (5' - 3')
<i>GAPDH</i>	AAGGGCTCATGACCACAGTC	GGATGACCTTGCCCACAG
<i>CD11b</i>	CGGAAGGATTCAGCAAGCCAGAAC	AGCTGGACTCAGCAGGCTTTAC
<i>CD11c</i>	TTGGGTGCCCATAGAGCTGAAG	CATTGGGTGAGTGGGTTCTGAG
<i>IFNγ</i>	CGGCACAGTCATTGAAAGCC	TGTCACCATCCTTTTGCCAGT
<i>IL-10</i>	AGGCGCTGTCATCGATTTCT	TGGCCTTGTAGACACCTTGG
<i>IL-1β</i>	TGCCACCTTTTGACAGTGATG	ATGTGCTGCTGCGAGATTTG
<i>IL-17A</i>	GCAGGAGAATTGCATCCTGGTGTG	AGGACACAAGACGTGCTTCCAG
<i>IL-23A</i>	GACTCAAGGACAACAGCCAGTTC	TCCTAGTAGGGAGGTGTGAAGTTG
<i>IL-33</i>	TCCAACCTCCAAGATTTCCCCG	CATGCAGTAGACATGGCAGAA
<i>TNF-α</i>	AGCCCACGTCGTAGCAAAC	TTTGAGATCCATGCCGTTGG
<i>Cytokeratin12</i>	CGCTGGGTCTCAGAGTGATT	CTGACTCTGGCAGAAACGATCTTA
<i>LYVE-1</i>	TGGGAAGAATGGCAAAGGTGTCC	ATGCAGGAGTTAACCAGGTGTCCG
<i>Pecam-1</i>	TTGAGCCTCACCAAGAGAACGG	ACTCTCGCAATCCAGGAATCGG
<i>VEGF-A</i>	TGTACCTCCACCATGCCAAGTG	TGGGACTTCTGCTCTCCTTCTGTC
<i>VEGF-C</i>	TCCTGGGAAATGTGCCTGTGAATG	GCACACGGTCTTCTGTAACAACCTG
<i>VEGFR-1</i>	GAGGAGGATGAGGGTGTCTATAGGT	GTGATCAGCTCCAGGTTTGACTT

<i>VEGFR-2</i>	GCCCTGCCTGTGGTCTCACTAC	CAAAGCATTGCCCATTCGAT
<i>VEGFR-3</i>	GTGCTCAAAGAGGTGACCGA	TGAGGAGGCACATTCACCAC

IFN; interferon, IL; interleukin, TNF; tumor necrosis factor, LYVE; lymphatic vessel

endothelial hyaluronan receptor, VEGF; vascular endothelial growth factor, VEGFR;

vascular endothelial growth factor receptor.